img

Global Oncology Immuno Drug Market Segment Research Report 2024


Published on: 2024-01-04 | No of Pages : 420 | Industry : Pharma & Healthcare Research Center

Publisher : MRX | Format : PDF

Global Oncology Immuno Drug Market Segment Research Report 2024

Summary

The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Oncology Immuno Drug Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Oncology Immuno Drug industry at home and abroad, estimate the overall market scale of the Oncology Immuno Drug industry and the market share of major countries, Oncology Immuno Drug industry, and study and judge the downstream market demand of Oncology Immuno Drug through systematic research, Analyze the competition pattern of Oncology Immuno Drug, so as to help solve the pain points of various stakeholders in Oncology Immuno Drug industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Oncology Immuno Drug Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Oncology Immuno Drug Market?
Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Major Type of Oncology Immuno Drug Covered in XYZResearch report
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Application Segments Covered in XYZResearch Market
Hospitals
Drugstores
Others

For any other requirements, please feel free to contact us and we will provide you customized report.

Table of Content

Table of Contents

Global Oncology Immuno Drug Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Oncology Immuno Drug Market by Value
2.2.1 Global Oncology Immuno Drug Revenue by Type
2.2.2 Global Oncology Immuno Drug Market by Value (%)
2.3 Global Oncology Immuno Drug Market by Production
2.3.1 Global Oncology Immuno Drug Production by Type
2.3.2 Global Oncology Immuno Drug Market by Production (%)

3. The Major Driver of Oncology Immuno Drug Industry
3.1 Historical & Forecast Global Oncology Immuno Drug Demand
3.2 Largest Application for Oncology Immuno Drug (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Oncology Immuno Drug Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Oncology Immuno Drug Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Oncology Immuno Drug Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Oncology Immuno Drug Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Oncology Immuno Drug Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Oncology Immuno Drug Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Oncology Immuno Drug Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Oncology Immuno Drug Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Oncology Immuno Drug Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Oncology Immuno Drug Average Price Trend
12.1 Market Price for Each Type of Oncology Immuno Drug in US (2018-2022)
12.2 Market Price for Each Type of Oncology Immuno Drug in Europe (2018-2022)
12.3 Market Price for Each Type of Oncology Immuno Drug in China (2018-2022)
12.4 Market Price for Each Type of Oncology Immuno Drug in Japan (2018-2022)
12.5 Market Price for Each Type of Oncology Immuno Drug in India (2018-2022)
12.6 Market Price for Each Type of Oncology Immuno Drug in Korea (2018-2022)
12.7 Market Price for Each Type of Oncology Immuno Drug in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Oncology Immuno Drug Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Oncology Immuno Drug

14. Oncology Immuno Drug Competitive Landscape
14.1 Bristol-Myers Squibb
14.1.1 Bristol-Myers Squibb Company Profiles
14.1.2 Bristol-Myers Squibb Product Introduction
14.1.3 Bristol-Myers Squibb Oncology Immuno Drug Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Merck & Co
14.2.1 Merck & Co Company Profiles
14.2.2 Merck & Co Product Introduction
14.2.3 Merck & Co Oncology Immuno Drug Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Roche AG
14.3.1 Roche AG Company Profiles
14.3.2 Roche AG Product Introduction
14.3.3 Roche AG Oncology Immuno Drug Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 AstraZeneca
14.4.1 AstraZeneca Company Profiles
14.4.2 AstraZeneca Product Introduction
14.4.3 AstraZeneca Oncology Immuno Drug Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Sanofi S.A.
14.5.1 Sanofi S.A. Company Profiles
14.5.2 Sanofi S.A. Product Introduction
14.5.3 Sanofi S.A. Oncology Immuno Drug Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Dendreon Pharmaceuticals
14.6.1 Dendreon Pharmaceuticals Company Profiles
14.6.2 Dendreon Pharmaceuticals Product Introduction
14.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Novartis
14.7.1 Novartis Company Profiles
14.7.2 Novartis Product Introduction
14.7.3 Novartis Oncology Immuno Drug Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Gilead Sciences Inc.
14.8.1 Gilead Sciences Inc. Company Profiles
14.8.2 Gilead Sciences Inc. Product Introduction
14.8.3 Gilead Sciences Inc. Oncology Immuno Drug Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Merck KGaA
14.9.1 Merck KGaA Company Profiles
14.9.2 Merck KGaA Product Introduction
14.9.3 Merck KGaA Oncology Immuno Drug Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
15. Conclusion
16. Methodology and Data Source


List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Oncology Immuno Drug Industry (Volume)
Figure 2. Oncology Immuno Drug Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Oncology Immuno Drug Revenue in 2022
Figure 5. US Oncology Immuno Drug Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Oncology Immuno Drug Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Oncology Immuno Drug Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Oncology Immuno Drug Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Oncology Immuno Drug Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Oncology Immuno Drug Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Oncology Immuno Drug Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Oncology Immuno Drug Revenue, by Type (Million USD) (2018-2028)
Table 4. Oncology Immuno Drug Production, by Type (K Unit) (2018-2028)
Table 5. Oncology Immuno Drug Demand (K Unit) by Application (2018-2028)
Table 6. Oncology Immuno Drug Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Oncology Immuno Drug Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Oncology Immuno Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Oncology Immuno Drug in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Bristol-Myers Squibb Profiles
Table 61. Bristol-Myers Squibb Oncology Immuno Drug Product Introduction
Table 62. Bristol-Myers Squibb Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Bristol-Myers Squibb Strategic initiatives
Table 64. Merck & Co Profiles
Table 65. Merck & Co Oncology Immuno Drug Product Introduction
Table 66. Merck & Co Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Merck & Co Strategic initiatives
Table 68. Roche AG Profiles
Table 69. Roche AG Oncology Immuno Drug Product Introduction
Table 70. Roche AG Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Roche AG Strategic initiatives
Table 72. AstraZeneca Profiles
Table 73. AstraZeneca Oncology Immuno Drug Product Introduction
Table 74. AstraZeneca Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. AstraZeneca Strategic initiatives
Table 76. Sanofi S.A. Profiles
Table 77. Sanofi S.A. Oncology Immuno Drug Product Introduction
Table 78. Sanofi S.A. Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Sanofi S.A. Strategic initiatives
Table 80. Dendreon Pharmaceuticals Profiles
Table 81. Dendreon Pharmaceuticals Oncology Immuno Drug Product Introduction
Table 82. Dendreon Pharmaceuticals Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Dendreon Pharmaceuticals Strategic initiatives
Table 84. Novartis Profiles
Table 85. Novartis Oncology Immuno Drug Product Introduction
Table 86. Novartis Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. Novartis Strategic initiatives
Table 88. Gilead Sciences Inc. Profiles
Table 89. Gilead Sciences Inc. Oncology Immuno Drug Product Introduction
Table 90. Gilead Sciences Inc. Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. Gilead Sciences Inc. Strategic initiatives
Table 92. Merck KGaA Profiles
Table 93. Merck KGaA Oncology Immuno Drug Product Introduction
Table 94. Merck KGaA Oncology Immuno Drug Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Merck KGaA Strategic initiatives